The evolving role of angiotensin-II receptor blockers in cardiovascular risk reduction. Case study.
Oparil
S
S
Vascular Biology and Hypertension Program of the Division of Cardiovascular Diseases, University of Alabama at Birmingham 35294, USA.
D000179:Acrylates / Q000627:therapeutic use; D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D044383:Black People; D004656:Enalapril / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000208:ethnology*; D007093:Imidazoles / Q000627:therapeutic use; D019808:Losartan / Q000627:therapeutic use*; D011945:Receptors, Angiotensin / Q000187:drug effects; D013876:Thiophenes
D000179:Acrylates; D000959:Antihypertensive Agents; D007093:Imidazoles; D011945:Receptors, Angiotensin; D013876:Thiophenes; C068373:eprosartan; D004656:Enalapril; D019808:Losartan